loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Cilastatin

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Cilastatin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,530Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Arch Biopartners' Cilastatin To Join PONTIAC Phase II Kidney Injury Trial
    Arch Biopartners' Cilastatin To Join PONTIAC Phase II Kidney Injury Trial

    02 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/02/2923541/0/en/Arch-Biopartners-Cilastatin-Drug-Candidate-to-Participate-in-the-PONTIAC-Phase-II-Trial-Targeting-Acute-Kidney-Injury-Caused-by-Drug-Toxins.html

    GLOBENEWSWIRE
    02 Aug 2024
    Share Share
    Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin
    Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin

    27 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/27/2835883/0/en/Arch-Biopartners-Has-Pre-IND-Meeting-With-FDA-to-Discuss-Repurposing-Cilastatin-as-a-New-Treatment-to-Prevent-Acute-Kidney-Injury.html

    GLOBENEWSWIRE
    27 Feb 2024
    Share Share
    Merck defends antibiotic's approval from 2019
    Merck defends antibiotic's approval from 2019

    17 May 2023

    // Zachary Brennan ENDPTS

    https://endpts.com/merck-defends-antibiotics-approval-from-2019-as-bmj-investigation-points-to-decline-in-fda-standards/

    Zachary Brennan ENDPTS
    17 May 2023
    Share Share
    Enforcement Report - Week of February 22, 2023
    Enforcement Report - Week of February 22, 2023

    22 Feb 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-22-2023-51785.pdf

    FDA
    22 Feb 2023
    Share Share
    Merck is shutting the doors at a 300-person plant in PA
    Merck is shutting the doors at a 300-person plant in PA

    25 Mar 2022

    // F. Kansteiner FIERCEPHARMA

    https://www.fiercepharma.com/pharma/merck-telegraphs-closure-pa-antibiotics-plant-employs-300

    F. Kansteiner FIERCEPHARMA
    25 Mar 2022
    Share Share
    FDA Approves Merck’s (imipenem, cilastatin, and relebactam) for the Treatment
    FDA Approves Merck’s (imipenem, cilastatin, and relebactam) for the Treatment

    05 Jun 2020

    // MERCK

    https://investors.merck.com/news/press-release-details/2020/FDA-Approves-Mercks-RECARBRIO-imipenem-cilastatin-and-relebactam-for-the-Treatment-of-Adults-with-Hospital-Acquired-and-Ventilator-Associated-Bacterial-Pneumonia-HABPVABP/default.aspx

    MERCK
    05 Jun 2020
    Share Share